Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew F Mescher

Showing results (1-10 of 35) with videos related to

Pageof 4
Sort By:
Journal of Immunology (Baltimore, Md. : 1950)|August 8, 2002
Opposing effects of IL-2 in tumor immunotherapy: promoting CD8 T cell growth and inducing apoptosisProtul Shrikant, Matthew F Mescher
Journal of Immunology (Baltimore, Md. : 1950)|August 8, 2002
The poststimulation program of CD4 versus CD8 T cells (death versus activation-induced nonresponsiveness)Ee Loon Tham, Matthew F Mescher
Journal of Immunology (Baltimore, Md. : 1950)|June 6, 2007
IL-21 promotes differentiation of naive CD8 T cells to a unique effector phenotypeKerry A Casey, Matthew F Mescher
Journal of Immunology (Baltimore, Md. : 1950)|February 24, 2009
Antigen processing and MHC-II presentation by dermal and tumor-infiltrating dendritic cellsMichael Y Gerner, Matthew F Mescher
Journal of Immunology (Baltimore, Md. : 1950)|May 23, 2002
Peptide antigen priming of naive, but not memory, CD8 T cells requires a third signal that can be provided by IL-12Clint S Schmidt, Matthew F Mescher
Journal of Immunology (Baltimore, Md. : 1950)|February 6, 2008
Antigen controls IL-7R alpha expression levels on CD8 T cells during full activation or tolerance inductionChristopher D Hammerbeck, Matthew F Mescher
Current Opinion in Immunology|April 6, 2010
Inflammatory cytokines as a third signal for T cell activationJulie M Curtsinger, Matthew F Mescher
Journal of Immunology (Baltimore, Md. : 1950)|December 24, 2002
In vivo augmentation of tumor-specific CTL responses by class I/peptide antigen complexes on microspheres (large multivalent immunogen)Jodi Goldberg, Protul Shrikant, Matthew F Mescher
Journal of Immunology (Baltimore, Md. : 1950)|January 22, 2002
Activation-induced nonresponsiveness: a Th-dependent regulatory checkpoint in the CTL responseEe Loon Tham, Protul Shrikant, Matthew F Mescher
The Journal of Experimental Medicine|October 24, 2007
Detuning CD8 T cells: down-regulation of CD8 expression, tetramer binding, and response during CTL activationZhengguo Xiao, Matthew F Mescher, Stephen C Jameson
Pageof 4

Showing results (1-10 of 35) with videos related to

Sort By:
Pageof 4
Journal of Immunology (Baltimore, Md. : 1950)|August 8, 2002
Opposing effects of IL-2 in tumor immunotherapy: promoting CD8 T cell growth and inducing apoptosisProtul Shrikant, Matthew F Mescher
Journal of Immunology (Baltimore, Md. : 1950)|August 8, 2002
The poststimulation program of CD4 versus CD8 T cells (death versus activation-induced nonresponsiveness)Ee Loon Tham, Matthew F Mescher
Journal of Immunology (Baltimore, Md. : 1950)|June 6, 2007
IL-21 promotes differentiation of naive CD8 T cells to a unique effector phenotypeKerry A Casey, Matthew F Mescher
Journal of Immunology (Baltimore, Md. : 1950)|February 24, 2009
Antigen processing and MHC-II presentation by dermal and tumor-infiltrating dendritic cellsMichael Y Gerner, Matthew F Mescher
Journal of Immunology (Baltimore, Md. : 1950)|May 23, 2002
Peptide antigen priming of naive, but not memory, CD8 T cells requires a third signal that can be provided by IL-12Clint S Schmidt, Matthew F Mescher
Journal of Immunology (Baltimore, Md. : 1950)|February 6, 2008
Antigen controls IL-7R alpha expression levels on CD8 T cells during full activation or tolerance inductionChristopher D Hammerbeck, Matthew F Mescher
Current Opinion in Immunology|April 6, 2010
Inflammatory cytokines as a third signal for T cell activationJulie M Curtsinger, Matthew F Mescher
Journal of Immunology (Baltimore, Md. : 1950)|December 24, 2002
In vivo augmentation of tumor-specific CTL responses by class I/peptide antigen complexes on microspheres (large multivalent immunogen)Jodi Goldberg, Protul Shrikant, Matthew F Mescher
Journal of Immunology (Baltimore, Md. : 1950)|January 22, 2002
Activation-induced nonresponsiveness: a Th-dependent regulatory checkpoint in the CTL responseEe Loon Tham, Protul Shrikant, Matthew F Mescher
The Journal of Experimental Medicine|October 24, 2007
Detuning CD8 T cells: down-regulation of CD8 expression, tetramer binding, and response during CTL activationZhengguo Xiao, Matthew F Mescher, Stephen C Jameson
Pageof 4